Eli Lilly to build a USD 2.5-billion plant in Germany

US-based Eli Lilly is planning a huge investment of USD 2.5 billion, equivalent to around SEK 26.5 billion, in a new production facility in Alzey, Germany.

Hon blir ny medicinsk chef på Synact Pharma

Synact Pharma, som bland annat utvecklar behandlingar för reumatiska sjukdomar, har utsett Kirsten Harting till ny Chief Medical Officer.

Study: Vaccination linked to lower risk of post-COVID

The risk of developing post-COVID after a COVID infection was reduced in vaccinated people, according to a new study from the University of Gothenburg.

Han är ny på Capitainer

Solnaföretaget Capitainer har anställt Johan Olausson som applikationsspecialist.

Suing the company – for NOT developing a new HIV drug

Was Gilead putting a steady flow of profits from its cash cow ahead of developing a new and safer drug? According to a large number of US HIV patients in a lega...

The Swedish Life Science Office: “We lost in both coordination and manpower”

Since the turn of the year, the Swedish government’s life science office has operated at a lower capacity. Life Science Sweden has spoken to Pontus Holm, Depart...

Søren Bregenholt omvald som ordförande i MVA

Under Medicon Valley Alliance årsstämma fick styrelsen förnyat förtroende och valdes om.

Hello Angelica Loskog!

Life Science Sweden would like to know more about Angelica Loskog and interviews her about her life as a researcher.

Tirzepatide approved for obesity by the FDA – to be branded as Zepbound

Diabetes drug tirzepatide has now also been approved in the US for treating obesity.

Studie med läkemedel mot nervsmärta startar

Lundaföretaget Pharmnovo påbörjar nu kliniska studier med sin läkemedelskandidat mot neuropatisk smärta.

Improve your secondary battery manufacturing

SMC provides a large portfolio of products specially designed for secondary battery industry.

Automated dispensing of liquids

Have a look at how you can do easier and faster dispensing on the fly adapted to your needs

Forskningsentreprenörens satsning ska förenkla forskning.

Cancerforskaren Sara Mangsbo vill förenkla det administrativa forskningsarbetet

Novo Nordisk to invest billions in Danish manufacturing facilities

Danish pharmaceutical giant Novo Nordisk is investing DKK 42 billion, equivalent to around SEK 65 billion/EUR 5.6 billion, in its manufacturing facilities in Ka...

High-tech companies are increasingly focusing on health

Tech companies have been taking an interest in healthcare for many years, and this interest seems to be increasing. “It’s not a sudden shift in trend, it’s more...

Webinar: How to Plan And Analyze a Real-World Evidence Study

This webinar is for drug developers who want to understand the basic ideas of analyzing an RWE study, as well as avoiding the most common pitfalls.

Pharma Outsourcing igång på Stockholm Waterfront

Mizarra Business Management

Heidi Stensmyren is eager for new challenges in the biotech industry

management roles,” she says.

Samuel Lagercrantz: The government’s performance in healthcare and life sciences so far

Since the change of government in Sweden, developments in the healthcare sector have shown promising signs, but the outlook in life sciences is less promising, ...

Charlotta Gummeson leaves Sahlgrenska Science Park – “It feels sad and exciting at the same time”

With mixed emotions, Charlotta Gummeson will leave her position as CEO of Sahlgrenska Science Park in October. “It feels sad and exciting at the same time. I’ve...

Anna Törner: The clinical trial – Periscope to reality

What happens to the patients in the clinical trial is not very interesting, writes Anna Törner in a column.

Ny modell ger ytterligare stöd för munskydd: ”Ger ett utmärkt skydd”

Forskare vid bland annat Chalmers har tagit fram en modell för att mäta hur virus färdas genom luften – och hur effektivt munskydd är för att hindra smittspridn...

The first drugs to slow down Alzheimer’s – but what does it mean for patients?

New treatments for early Alzheimer’s are bringing hope to thousands of patients and their families. The question is, who will get the treatment, how will the ri...